Im Seock-Ah
Cited by
Cited by
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
J Baselga, J Cortés, SB Kim, SA Im, R Hegg, YH Im, L Roman, JL Pedrini, ...
New England Journal of Medicine 366 (2), 109-119, 2012
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
P Schmid, S Adams, HS Rugo, A Schneeweiss, CH Barrios, H Iwata, ...
New England Journal of Medicine 379 (22), 2108-2121, 2018
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised ・
L Gianni, T Pienkowski, YH Im, L Roman, LM Tseng, MC Liu, A Lluch, ...
The lancet oncology 13 (1), 25-32, 2012
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
M Robson, SA Im, E Senkus, B Xu, SM Domchek, N Masuda, S Delaloge, ...
New England Journal of Medicine 377 (6), 523-533, 2017
Palbociclib and letrozole in advanced breast cancer
RS Finn, M Martin, HS Rugo, S Jones, SA Im, K Gelmon, N Harbeck, ...
New England journal of medicine 375 (20), 1925-1936, 2016
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous ・
M Cristofanilli, NC Turner, I Bondarenko, J Ro, SA Im, N Masuda, ...
The Lancet Oncology 17 (4), 425-439, 2016
Adjuvant capecitabine for breast cancer after preoperative chemotherapy
N Masuda, SJ Lee, S Ohtani, YH Im, ES Lee, I Yokota, K Kuroi, SA Im, ...
New England Journal of Medicine 376 (22), 2147-2159, 2017
Predictive and prognostic impact of epidermal growth factor receptor mutation in non–small-cell lung cancer patients treated with gefitinib
SW Han, TY Kim, PG Hwang, S Jeong, J Kim, IS Choi, DY Oh, JH Kim, ...
Journal of clinical oncology 23 (11), 2493-2501, 2005
Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
S Modi, C Saura, T Yamashita, YH Park, SB Kim, K Tamura, F Andre, ...
New England Journal of Medicine 382 (7), 610-621, 2020
Overall survival with palbociclib and fulvestrant in advanced breast cancer
NC Turner, DJ Slamon, J Ro, I Bondarenko, SA Im, N Masuda, M Colleoni, ...
New England journal of medicine 379 (20), 1926-1936, 2018
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre ・
L Gianni, T Pienkowski, YH Im, LM Tseng, MC Liu, A Lluch, ...
The lancet oncology 17 (6), 791-800, 2016
Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3
DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ...
Journal of Clinical Oncology 36 (24), 2465-2472, 2018
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
D Tripathy, SA Im, M Colleoni, F Franke, A Bardia, N Harbeck, SA Hurvitz, ...
The Lancet Oncology 19 (7), 904-915, 2018
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
A de Gramont, E Van Cutsem, HJ Schmoll, J Tabernero, S Clarke, ...
The lancet oncology 13 (12), 1225-1233, 2012
Overall survival with ribociclib plus endocrine therapy in breast cancer
SA Im, YS Lu, A Bardia, N Harbeck, M Colleoni, F Franke, L Chow, J Sohn, ...
New England journal of medicine 381 (4), 307-316, 2019
Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer
KS Lee, HC Chung, SA Im, YH Park, CS Kim, SB Kim, SY Rha, MY Lee, ...
Breast cancer research and treatment 108 (2), 241-250, 2008
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ...
The lancet oncology 18 (12), 1688-1700, 2017
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
D Cameron, J Brown, R Dent, C Jackisch, J Mackey, X Pivot, GG Steger, ...
The lancet oncology 14 (10), 933-942, 2013
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355 ・
J Cortes, DW Cescon, HS Rugo, Z Nowecki, SA Im, MM Yusof, C Gallardo, ...
The Lancet 396 (10265), 1817-1828, 2020
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double ・
J Baselga, SA Im, H Iwata, J Cortés, M De Laurentiis, Z Jiang, CL Arteaga, ...
The Lancet Oncology 18 (7), 904-916, 2017
The system can't perform the operation now. Try again later.
Articles 1–20